The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.
about
Erlotinib for advanced pancreatic cancerSystematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaSystemic therapies for pancreatic cancer--the role of pharmacogeneticsTumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progressionHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerTargeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implicationsGemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysisOutcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.Evolution of systemic therapy for advanced pancreatic cancer.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-AnalysisExpression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis.Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src.Targeted therapies for pancreatic cancer.Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma.Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancerEpidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckMaximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group StudyRON is not a prognostic marker for resectable pancreatic cancer.Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growthCurrent immunotherapeutic approaches in pancreatic cancer.Pancreatic cancer stromal biology and therapy.Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptorThe pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancerEGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.Emerging therapies in pancreas cancer.Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancersMembranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma.Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways.Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.Update on pancreatic cancer and alcohol-associated risk.EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
P2860
Q24186983-FE481679-0DA3-4391-90FD-78DF6D92E645Q26739910-041FFCDD-1A8A-4136-89FF-BFF27FE1994FQ27021716-9C4CC28C-02EF-4791-9D84-1A533277C970Q28072763-81F80E35-CFF0-48A9-830E-EA7AED397CABQ28078111-5F62D6AB-2710-469B-BC19-937ED4390CE8Q28084216-85D3AED8-DFC3-47B3-A855-E6932268B98EQ28269990-F847D6D2-C820-425F-AC04-C3ABB5D1FACFQ28487656-15FDB49C-77BC-47C3-BF58-4AC2DAA9D647Q33417105-F28D9AF4-6197-45E2-92AB-4C91A4778445Q33557413-ED26FB5B-27FF-48EA-AC60-375DB533757AQ33754779-4C9A3409-8957-4489-B17B-5A12FBF93F95Q33772907-9C9ACB58-8371-4286-85DB-ACF040F4434EQ33788222-2EC83F5C-4672-4691-A9E5-99C2BA8D4875Q33861952-CD69A0EE-1C8E-4B83-8ED4-37BA0354B90DQ33899923-7E9406DA-CE06-4AA5-ADDA-5B17DF35CA03Q34017423-0D98D575-1598-4016-96ED-38F3ACA08545Q34049250-BC5A25EA-F7C6-4CA1-8404-918C7493D5C3Q34128530-B10D59C5-307A-41C8-A03C-322B80A8A883Q34159125-4A3AF94F-5FC9-41B2-89EB-D0F08F071946Q34243313-248B15C0-D9DA-4839-98A0-142B212DCC24Q34257664-1F297988-FC03-49F9-8667-9EFD21299448Q34408923-E8E519AF-73F3-40DE-B725-7E162D2C43AEQ34496697-DDCC235C-1E16-4A68-910B-081502ABC790Q34812100-E94BA4B8-9478-4121-B6E8-13E4DD3D505BQ35212837-667009D2-8F77-4725-8F34-49280C4B3AE9Q35766799-3838EEDA-F060-4E2B-B05A-091947398416Q35870242-75A2466B-718E-42E9-8F96-344614BFE68AQ35896807-D41C00D8-AF00-49CC-BA91-9951283F6C90Q36014277-BCB64429-8291-41C0-8CF3-DCF1B21F1BDDQ36014381-9F372B14-4E91-408B-8277-CEB7D4CAF5A6Q36064511-CDAE486A-8535-418F-B914-DC3CEBB1DC8DQ36097144-44DC8970-179B-4A17-8CB6-CFCE27C4C932Q36217036-772FB938-9411-471F-8545-D5738FB655A4Q36224439-57D00095-2467-4C31-AD76-87AB48E713ABQ36410371-AA2C2873-C8EE-4534-BEA4-E15BCF28ADCAQ36466176-854136F3-4B8B-4E52-BCEC-1E6249F216A6Q36525403-ABF435B8-A48D-4AEC-AE40-6D39C7ED1E5FQ36582547-1824DD13-9004-440D-A63C-14A9F5AD1A65Q36588233-DB59C09E-032D-46F8-A13C-9CBE0F279142Q36594155-CE7F9187-E8D9-445C-8B40-D40431C3EB01
P2860
The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The correlation between cytopl ...... creatic ductal adenocarcinoma.
@en
type
label
The correlation between cytopl ...... creatic ductal adenocarcinoma.
@en
prefLabel
The correlation between cytopl ...... creatic ductal adenocarcinoma.
@en
P2093
P921
P1433
P1476
The correlation between cytopl ...... creatic ductal adenocarcinoma.
@en
P2093
Hidetaka Mochizuki
Hitoshi Tsuda
Kazuo Hatsuse
Mikihiko Kimura
Nobuaki Kawarabayashi
Osamu Matsubara
Seiichi Tamai
Shigeto Ueda
Yoshiaki Sugiura
P356
10.1097/00006676-200407000-00061
P577
2004-07-01T00:00:00Z